in our genes.
Transforming treatment of severe disease with genetic medicines for tissue regeneration and organ repair.
YAP Therapeutics, a Fjord Ventures Company, was founded with technology licensed from Texas Heart Institute and Baylor College of Medicine to develop and commercialize genetic medicines that regenerate tissue and repair organs for patients suffering from severe disease.
The YAPtx technology platform for regeneration and antifibrosis has its roots in modulation of Hippo/ YAP signaling as well as other related pathways. The genetic medicines under development are designed to unlock the regenerative capacity naturally contained within our DNA. These medicines will be delivered via recombinant viral vectors (like AAV) and next generation non-viral means. YAPtx is deploying its technology platform in order to realize the full potential of regenerative medicine to repair organs and cure severe disease for millions of patients.